WO2004013100A3 - Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique - Google Patents

Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique Download PDF

Info

Publication number
WO2004013100A3
WO2004013100A3 PCT/FR2003/002355 FR0302355W WO2004013100A3 WO 2004013100 A3 WO2004013100 A3 WO 2004013100A3 FR 0302355 W FR0302355 W FR 0302355W WO 2004013100 A3 WO2004013100 A3 WO 2004013100A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
phenyl
optionally substituted
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/002355
Other languages
English (en)
Other versions
WO2004013100A2 (fr
Inventor
Emmanuelle Dachary
Gihad Dargazanli
Genevieve Estenne-Bouhtou
Benoit Marabout
Nathalie Rakotoarisoa
Pierre Roger
Mireille Sevrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Priority to AU2003273474A priority Critical patent/AU2003273474A1/en
Publication of WO2004013100A2 publication Critical patent/WO2004013100A2/fr
Publication of WO2004013100A3 publication Critical patent/WO2004013100A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composés de formule générale (I) où R1 représente H ou un alkyle, cycloalkylalkyle, phénylalkyle, alcényle ou alcynyle, X représente soit H ou un ou plusieurs atomes d'halogènes, alkyle ou alcoxy, R2 représente H ou un ou plusieurs atomes d'halogènes ou groupes alcoxy, ou amino éventuellement substitué, R3 représente soit un groupe aminosulfonyle éventuellement substitué, soit un groupe cyano ou un groupe de formule S-alkyle, soit un groupe alkylsulfonyle, soit un groupe carboxy ou alcoxycabonyle, soit un groupe carbamoyle éventuellement substitué, soit un groupe acétyle ou benzoyle, soit un groupe alkyle, cycloalkyle, alcényle, phényle, thiényle ou thianthrényle. Application en thérapeutique.
PCT/FR2003/002355 2002-07-29 2003-07-25 Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique Ceased WO2004013100A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003273474A AU2003273474A1 (en) 2002-07-29 2003-07-25 Less thanigreater thannless than/igreater than-(phenyl(piperidin-2-yl)methyl)benzamide derivatives, preparation thereof, and use thereof in therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0209589A FR2842805A1 (fr) 2002-07-29 2002-07-29 Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide,leur preparation et leur application et therapeutique
FR02/09589 2002-07-29

Publications (2)

Publication Number Publication Date
WO2004013100A2 WO2004013100A2 (fr) 2004-02-12
WO2004013100A3 true WO2004013100A3 (fr) 2004-04-15

Family

ID=30011557

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/002355 Ceased WO2004013100A2 (fr) 2002-07-29 2003-07-25 Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique

Country Status (3)

Country Link
AU (1) AU2003273474A1 (fr)
FR (1) FR2842805A1 (fr)
WO (1) WO2004013100A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227930B2 (en) 2010-08-13 2016-01-05 Abbvie Inc. Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9238619B2 (en) 2010-08-13 2016-01-19 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586942B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408774D0 (en) * 2004-04-20 2004-05-26 Glaxo Group Ltd Compounds
JP5123669B2 (ja) * 2005-01-14 2013-01-23 エム・エス・ディー・オス・ベー・フェー 薬物およびアルコール依存症を治療するためのグリシン再取込みインヒビター
CA2611376C (fr) 2005-06-13 2013-09-10 Merck Sharp & Dohme Limited Agents therapeutiques
EP2178842A2 (fr) 2007-08-22 2010-04-28 Abbott GmbH & Co. KG 4-benzylaminoquinolines, compositions pharmaceutiques les contenant et leur utilisation
ES2397764T3 (es) 2008-04-01 2013-03-11 Abbott Gmbh & Co. Kg Tetrahidroisoquinolinas, composiciones farmacéuticas que las contienen, y su uso en terapia
AR075182A1 (es) * 2009-01-28 2011-03-16 Astrazeneca Ab Compuestos 2-aza-biciclo (2.2.2) octano y sus usos
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
FR2943056A1 (fr) * 2009-03-16 2010-09-17 Sanofi Aventis Derives de n-°2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
CA2755526A1 (fr) * 2009-03-16 2010-09-23 Sanofi Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutique
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
MY157429A (en) 2011-06-24 2016-06-15 Amgen Inc Trpm8 antagonists and their use in treatments
JP2014517074A (ja) 2011-06-24 2014-07-17 アムジエン・インコーポレーテツド Ｔｒｐｍ８アンタゴニストおよび治療におけるそれらの使用
JP2014521682A (ja) 2011-08-05 2014-08-28 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノクロマン、アミノチオクロマンおよびアミノ−１，２，３，４−テトラヒドロキノリン誘導体、これらを含有する医薬組成物、ならびに治療におけるこれらの使用
EP2780328A1 (fr) 2011-11-18 2014-09-24 Abbvie Deutschland GmbH & Co. KG Dérivés aminobenzocycloheptène, aminotétraline, aminoindane et phénalkylamine n-substitués, composition pharmaceutiques les contenant, et leur application thérapeutique
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
WO1999045011A1 (fr) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Inhibiteurs du transport de la glycine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
WO1999045011A1 (fr) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Inhibiteurs du transport de la glycine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
O. FRIELICH ET AL.: "Asymmetric synthesis. 39. Synthesis of 2-(1-aminoalkyl)piperidines via 2-cyano-6-phenyl oxazolopiperidine", J. ORG. CHEM., vol. 61, 1996, pages 6700 - 6705, XP002235079 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227930B2 (en) 2010-08-13 2016-01-05 Abbvie Inc. Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9238619B2 (en) 2010-08-13 2016-01-19 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586942B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9586945B2 (en) 2013-10-17 2017-03-07 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy

Also Published As

Publication number Publication date
AU2003273474A8 (en) 2004-02-23
FR2842805A1 (fr) 2004-01-30
AU2003273474A1 (en) 2004-02-23
WO2004013100A2 (fr) 2004-02-12

Similar Documents

Publication Publication Date Title
WO2004013101A3 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
NO20062031L (no) Derivater av N-[fenyl(alkylptpertdtn-2-yl)metyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske media
WO2005037781A3 (fr) Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
NO20062032L (no) Derivater av N-[fenyl(pyrrolidin-2-yl)-metyl]benzamid og N-[(azepan-2-yl)fenylmetyl]benzamid, fremgangsmate for fremstilling derav og anvendelse derav i terapeutiske midler
MA27192A1 (fr) Derives de n- (phenyl(piperidin-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
WO2005074643A3 (fr) Composes chimiques
WO2004031401A3 (fr) Nouveaux inhibiteurs de tyrosine kinases
NO20070555L (no) Kinazolinonderivater som parp-inhibitorer
ATE394383T1 (de) Biphenylkarbonsäureamidderivate als p38 kinase- inhibitoren
NO20064077L (no) Kemokinreseptorantagonister
IL180147A0 (en) N - (1 - (1 - benzyl - 4 - phenyl - 1h-imidazol - 2 - yl) - 2,2 - dymethylpropyl) benzamide derivatives and related compounds as kinesin spidle protein (ksp) inhibitors for the treatment of cancer
EP1619180A4 (fr) ANTAGONISTE DE CaSR
CO5251427A1 (es) Oxazolidinonas que tienen la fucion de sulfoximina
NO20072053L (no) Nye bis-azaindolderivater, fremstilling og farmasoytisk anvendelse derav som kinaseinhibitorer
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
AR046131A1 (es) Formas cristalinas de {2-[1-(3,5- bistrifluorurometilbencil)-5- piridin-4-il-1h-[1,2,3]triazol- 4-il]piridin- 3-il}-(2-clorofenil)metanona
SE0203303D0 (sv) Novel Compounds
EP1636182A4 (fr) Promedicaments d'inhibiteurs de kinesine mitotique
TW200633984A (en) Amide compounds and activators of thrombopoietin receptor
UY27587A1 (es) Heterociclos terapéuticos
CO5170535A1 (es) Derivados de n-[2-(4-aminofenil)etil]2,3-dihidro-1,4- benzodioxin-2-metanamina, su preparacion y su aplciacion en terapeutica
EE200100646A (et) Melagatraani peaaegu kristalne vorm
SE0302571D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP